References
- Blasi F, Mantero M, Santus P, et al. Understanding the burden of pneumococcal disease in adults. Clin Microbiol Infect. 2012;18:7–14.
- Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67(1):71–79.
- Ganaie F, Saad JS, McGee L, et al. A new pneumococcal capsule type, 10D, is the 100th serotype and has a large cps fragment from an oral Streptococcus. McDaniel LS, editor. mBio. 2020;11(3):e00937.
- Grant LR, Slack MPE, Yan Q, et al. The epidemiologic and biologic basis for classifying older age as a high-risk, immunocompromising condition for pneumococcal vaccine policy. Expert Rev Vaccines. 2021;20(6):691–705.
- Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1(1):ofu024.
- van Hoek AJ, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012;65(1):17–24.
- Andersen MA, Niemann CU, Rostgaard K, et al. Differences and temporal changes in risk of invasive pneumococcal disease in adults with hematological malignancies: results from a nationwide 16-Year cohort study. Clin Infect Dis. 2021;72(3):463–471.
- Navarro-Torné A, Dias JG, Hruba F, et al. Risk factors for death from invasive pneumococcal disease, Europe, 2010. Emerg Infect Dis. 2015;21(3):417–425.
- Statens Serum Institut. Pneumokokvaccination uden for børnevaccinationsprogrammet i Danmark [Pneumococcal Vaccination Outside the Danish Childhood Vaccination Program] [Internet]. 2020 [cited 2022 Apr 23]. Available from: https://en.ssi.dk/-/media/arkiv/dk/vaccination/risikogrupper/rapport-vedr-pneumokokvacc-udenfor-boernevaccprogram-14042020.pdf?la=en.
- Pelton SI, Shea KM, Weycker D, et al. Rethinking risk for pneumococcal disease in adults: the role of risk stacking. Open Forum Infect Dis. 2015;2(1):ofv020.
- Harboe ZB, Dalby T, Weinberger DM, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014;59(8):1066–1073.
- Hanquet G, Krizova P, Dalby T, et al. Serotype replacement after introduction of 10-Valent and 13-Valent pneumococcal conjugate vaccines in 10 countries, Europe. Emerg Infect Dis. 2022;28(1):137–138.
- Statens Serum Institut. Invasive pneumococcal disease and coverage of pneumococcal vaccination in the childhood vaccination programme, 2018 and 2019. Report No. 10. Copenhagen March 2020 Available from: https://en.ssi.dk/surveillance-and-preparedness/surveillance-in-denmark/annual-reports-on-disease-incidence/invasive-pneumococcal-disease-2018-2019
- Statens Serum Institut. Annual report: Invasive pneumococcal disease and coverage of pneumococcal vaccination in the childhood vaccination programme 2018 and 2019 [Internet]. 2020 [cited 2022 Feb 18]. Available from: https://en.ssi.dk/surveillance-and-preparedness/surveillance-in-denmark/annual-reports-on-disease-incidence/invasive-pneumococcal-disease-2018-2019.
- Statens Serum Institut. EPI-NYT No 7/8 - 2010 -PCV 7 coverage & Invasive Pneumococcal Disease (IPD) 2008/2009 [Internet]. 2010 [cited 2022 Feb 24]. Available from: https://en.ssi.dk/news/epi-news/2010/no-7-8–-2010
- Statens Serum Institut. EIP-NEWS (No 51b - 2012) - Pneumococcal vaccination of persons at increased risk of invasive pneumococcal disease [Internet]. 2012. Available from: https://en.ssi.dk/news/epi-news/2012/no-51b.
- Statens Serum Institut. EPI-NYT Uge 14/16 - Vaccinationsprogram mod pneumokoksygdom til personer der er fyldt 65 år og til risikogrupper [Pneumococcal vaccination program for persons 65 years or older and risk groups] [Internet]. 2020 [cited 2022 Feb 22]. Available from: https://www.ssi.dk/aktuelt/nyhedsbreve/epi-nyt/2020/uge-14-16. –2020.
- Statens Serum Institut. EPI-NYT No 49/50 - Extension of the invasive pneumococcal disease vaccination programme [Internet]. 2022. [cited 2022 Feb 22]. Available from: https://en.ssi.dk/news/epi-news/2021/no-49-50-2021.
- Sundhedsministeriet [The Danish Ministry of Health]. Bekendtgørelse om gratis vaccination mod influenza, pneumokokker og COVID-19 til visse persongrupper (BEK nr 1260 af 09/09/2022) [Notice about free influenza, pneumococcal and COVID-19 vaccination] [Internet]. 2022. [cited 2022 Oct 5]. Available from: https://www.retsinformation.dk/eli/lta/2022/1260.
- Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein–polysaccharide conjugate vaccines. Nat Rev Immunol. 2009;9(3):213–220.
- Clutterbuck EA, Lazarus R, Yu L-M, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis. 2012;205(9):1408–1416.
- Pletz MW, Maus U, Krug N, et al. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents. 2008;32(3):199–206.
- Jochems SP, Weiser JN, Malley R, et al. The immunological mechanisms that control pneumococcal carriage. Dehio C, editor. PLoS Pathog. 2017;13(12):e1006665.
- Collins AM, Wright AD, Mitsi E, et al. First human challenge testing of a pneumococcal vaccine. Double-blind randomized controlled trial. Am J Respir Crit Care Med. 2015;192(7):853–858.
- German EL, Solórzano C, Sunny S, et al. Protective effect of PCV vaccine against experimental pneumococcal challenge in adults is primarily mediated by controlling colonisation density. Vaccine. 2019;37(30):3953–3956.
- Adler H, German EL, Mitsi E, et al. Experimental human pneumococcal colonization in older adults Is feasible and safe, not immunogenic. Am J Respir Crit Care Med. 2021;203(5):604–613.
- European Commission. Union Register of medicinal products for human use - Apexxnar [Internet]. 2022 [cited 2022 Feb 28]. Available from: https://ec.europa.eu/health/documents/community-register/html/h1612.htm.
- European Medicines Agenc. Summary of Product Characteristics (Apexxnar) [Internet]. 2022 [cited 2022 Sep 27]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/apexxnar.
- Palmborg A, Skovdal M, Molden T, et al. Invasive pneumococcal disease (IPD) among elderly in Nordic countries: different needs for broader protection. ECCMID poster (abstract #03702) 2021.
- Cannon K, Elder C, Young M, et al. A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination. Vaccine. 2021;39(51):7494–7502.
- Essink B, Sabharwal C, Cannon K, et al. Pivotal phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged ≥18 years. Clin Infect Dis. 2022;75(3):390–398.
- Klein NP, Peyrani P, Yacisin K, et al. A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age. Vaccine. 2021;39(38):5428–5435.
- Bonten MJM, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114–1125.
- Hak E, Grobbee DE, Sanders EaM, et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med. 2008;66(9):378–383.
- Patterson S, Webber C, Patton M, et al. A post hoc assessment of duration of protection in CAPiTA (community acquired pneumonia immunization trial in adults). Trials Vaccinol. 2016;5:92–96.
- Moberley S, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Chichester (UK): John Wiley & Sons, Ltd; 2008. [cited 2022 Feb 23]. p. CD000422.pub2. Available from: https://doi.wiley.com/10.1002/14651858.CD000422.pub2.
- Tin Tin Htar M, Stuurman AL, Ferreira G, et al. Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies. Arez AP, editor. PLoS One. 2017;12(5):e0177985.
- Latifi-Navid H, Latifi-Navid S, Mostafaiy B, et al. Pneumococcal disease and the effectiveness of the PPV23 vaccine in adults: a two-stage Bayesian meta-analysis of observational and RCT reports. Sci Rep. 2018;8(1):11051.
- Andrews NJ, Waight PA, George RC, et al. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012;30(48):6802–6808.
- Djennad A, Ramsay ME, Pebody R, et al. Effectiveness of 23-valent polysaccharide pneumococcal vaccine and changes in invasive pneumococcal disease incidence from 2000 to 2017 in those aged 65 and over in England and Wales. EClinicalMedicine. 2018;6:42–50.
- Berild JD, Winje BA, Vestrheim DF, et al. A systematic review of studies published between 2016 and 2019 on the effectiveness and efficacy of pneumococcal vaccination on pneumonia and invasive pneumococcal disease in an elderly population. Pathogens. 2020;9(4):259.
- Statens Serum Institut. Vacciner der ikke betales af det offentlige [Vaccines not payed by the state] [Internet]. 2022 [cited 2022 Oct 10]. Available from: https://www.ssi.dk/vaccinationer/vacciner-der-ikke-betales-af-det-offentlige
- Data extraction from the Danish National Patient Register. Landspatientregisteret [National Patient Register]; 2017–2019.
- Danmarks Statistik [Statistics Denmark]. Population figures in Denmark (1st quarter 2018) - table FOLK1A [Internet]. [cited 2022 Jan 15]. Available from: https://www.dst.dk/da/Statistik/emner/borgere/befolkning/befolkningstal.
- Woodhead MA, Macfarlane JT, Mccracken JS, et al. Prospective study of the aetiology and outcome of pneumonia in the community. The Lancet. 1987;329(8534):671–674.
- Danmarks Statistik [Statistics Denmark]. Deaths by sex, age and cause of death (Table DOD1) [Internet]. [cited 2022 Jan 15]. Available from: https://www.statistikbanken.dk/DOD1.
- Ara R, Brazier JE. Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. Value Health. 2011;14(4):539–545.
- Mangen M-JJ, Huijts SM, Bonten MJM, et al. The impact of community-acquired pneumonia on the health-related quality-of-life in elderly. BMC Infect Dis. 2017;17(1):208.
- Disease data for pneumococcal disease from ECDC Surveillance Atlas [Internet]. ECDC; 2019. Available from: https://www.ecdc.europa.eu/en/pneumococcal-disease/surveillance-and-disease-data/atlas.
- Danish Ministry of Finance. Dokumentationsnotat – den samfundsøkonomiske diskonteringsrente [Note - the socio-economic discount rate] [Internet]. 2021 [cited 2022 Feb 11]. Available from: https://fm.dk/media/18371/dokumentationsnotat-for-den-samfundsoekonomiske-diskonteringsrente_7-januar-2021.pdf
- Mangen M-JJ, Rozenbaum MH, Huijts SM, et al. Cost-effectiveness of adult pneumococcal conjugate vaccination in The Netherlands. Eur Respir J. 2015;46(5):1407–1416.
- Heo JY, Seo YB, Choi WS, et al. Effectiveness of pneumococcal vaccination against pneumococcal pneumonia hospitalization in older adults: a prospective, test-negative study. J Infect Dis. 2022;225(5):836–845.
- Kim JH, Chun BC, Song JY, et al. Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: a case-control study. Vaccine. 2019;37(21):2797–2804.
- Essink B, Sabharwal C, Xu X, et al. 3. Phase 3 pivotal evaluation of 20-valent pneumococcal conjugate vaccine (PCV20) safety, tolerability, and immunologic noninferiority in participants 18 years and older. Open Forum Infect Dis. 2020;7(Supplement_1):S2–S2.
- Praktiserende Laegers Organisation. PLO takster (2022) [Internet]. 2022. Available from: https://www.laeger.dk/sites/default/files/honorartabel_2022_oktober.pdf.
- Brogaard SL, Nielsen MBD, Nielsen LU, et al. Health care and social care costs of pneumonia in Denmark: a register-based study of all citizens and patients with COPD in three municipalities. COPD. 2015;10:2303–2309.
- Sundhedsdatastyrelsen [The Danish Health Data Authority]. DRG-takster [DRG tariffs] [Internet]. 2022. Available from: https://sundhedsdatastyrelsen.dk/da/afregning-og-finansiering/takster-drg/takster-2022.
- Gustafsson N, Stallknecht SE, Skovdal M, et al. Societal costs due to meningococcal disease: a national registry-based study. Clinicoecon Outcomes Res. 2018;volume10:563–572.
- Medicinpriser.dk. Medicinpriser.dk [Internet] 2022 [cited 2022 Sep 5]. Available from: https://medicinpriser.dk/Default.aspx?id=15&vnr=373611
- Medicinrådet [The Danish Medicines Council]. Vaerdisaetning af enhedsomkostninger, version 1.6 [Valuation of unit costs, version 1.6] [Internet]. 2022 [cited 2022 Apr 24]. Available from: https://medicinraadet.dk/media/aunbprvq/v%C3%A6rdis%C3%A6tning-af-enhedsomkostninger-vers-1-6_adlegacy.pdf.
- Forbrugerprisindeks [Consumer price index] [Internet]. Danmarks Statistik [Statistics Denmark] 2022. Available from: https://www.statistikbanken.dk/PRIS111.
- Danmarks Nationalbank [Danish national bank]. Valutakurser DKK til EUR (16. September 2022) [Exchange rate DKK to EUR (16 September 2022)] [Internet]. 2022 [cited 2022 Feb 16]. Available from: https://www.nationalbanken.dk/valutakurser.
- Medicinrådet [Danish Medicines Council]. Medicinrådets metodevejledning for vurdering af nye laegemidler (Version 1.2) [The Danish Medicines Council’s process guide for assessing new pharmaceuticals] [Internet]. 2021 [cited 2022 Apr 24]. Available from: https://medicinraadet.dk/media/hciai0yz/medicinr%C3%A5dets_metodevejledning_for_vurdering_af_nye_l%C3%A6gemidler-vers-_1-2_adlegacy.pdf
- Lawrence H, Pick H, Baskaran V, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: a case-control test-negative design study. Kretzschmar MEE, editor. PLoS Med. 2020;17(10):e1003326.
- Falkenhorst G, Remschmidt C, Harder T, et al. Effectiveness of the 23-Valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysis. PLoS One. 2017;12(1):e0169368.
- Sundheds- og AEldreministeriet. Vejledning om udarbejdelse af sundhedsøkonomiske analyser af laegemidler (VEJ nr 9153) [Internet]. 2018. Available from: https://www.retsinformation.dk/eli/retsinfo/2018/9153.
- Chandler T, Furmanek S, Carrico R, et al. 23-Valent pneumococcal polysaccharide vaccination does not prevent community-acquired pneumonia hospitalizations due to vaccine-type Streptococcus pneumoniae. Microorganisms. 2022;10(3):560.
- Kolditz M, Schmitt J, Pletz MW, et al. Impact of the 13-valent pneumococcal conjugate vaccine on the incidence of all-cause pneumonia in adults aged ≥60 years: a population-based, retrospective cohort study. Clin Infect Dis. 2019;68(12):2117–2119.
- McLaughlin JM, Jiang Q, Isturiz RE, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine Against hospitalization for community-acquired pneumonia in older US adults: a test-negative design. Clin Infect Dis. 2018;67(10):1498–1506.
- Birck AM, Nordin Christensen L, Pedersen MH, et al. Health economic evaluation of introducing a PPSV23-based vaccination programme to adults aged 65 and above, and an extension to the 60-64 age group in Denmark. Expert Rev Vaccines. 2021;20(10):1327–1337.
- Benfield T, Skovgaard M, Schønheyder HC, et al. Serotype distribution in non-bacteremic pneumococcal pneumonia: association with disease severity and implications for pneumococcal conjugate vaccines. Beall B, editor. PLoS One. 2013;8(8):e72743.
- Theilacker C. Pneumococcal serotype distribution in adults hospitalized with radiologically-confirmed community-aquired pneumonia in Malmö, Sweden [Internet] 2020. Available from: https://cslide.ctimeetingtech.com/isppd20/attendee/eposter/poster/904?q=Theilacker.